Clinical Trial: Silymarin Versus N-Acetylcysteine as Protective Effect Against Anti-tuberculosis Drugs Induced Liver Injury.

U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07875322) titled 'Silymarin Versus N-Acetylcysteine as Protective Effect Against Anti-tuberculosis Drugs Induced Liver Injury.' on Sept. 25.

Brief Summary: Worldwide, tuberculosis (TB) infection caused by Mycobacterium Tuberculosis, remains one of the top 10 deadly diseases having a significant socioeconomic burden in the world, especially in developing countries. According to global estimates, the latest global TB report indicates that in 2022, roughly 1.3 million individuals died from TB.

The WHO estimated the TB incidence in Egypt in 2019 is 12,000 per 100,000 population. Although Between 1990 and 2019, TB incidence in Egypt declined from 35 to 1...